All
Retinoic acid metabolism inhibitor causes less irritation
October 1st 2001Washington - A series of cutaneous pharmacology studies conductedwith a selective retinoic acid metabolism inhibitor suggest this novel compoundhas the potential for treating a variety of retinoid-responsive dermatologicdiseases but with the advantage of causing less irritation compared to retinoicacid, Gerard J. Gendimenico, Ph.D., said at the Society for InvestigativeDermatology meeting.
Customized intervention offers onychomycosis solution
September 1st 2001Brugge, Belgium - Recalcitrant cases of onychomycosis can usually be treated successfully by following an individualized approach to further management that is based on confirmation of the diagnosis and investigation of contributing causes for prior treatment failure, Christa de Cuyper, M.D., said.
Engineered Tissue Successfully Heals Diabetic Ulcers Over 12 Weeks
September 1st 2001NEW YORK - OrCel, an engineered tissue produced by Ortec International, showed greater than 100 percent improvement over standard of care in diabetic ulcers the size of 6 cm2 or less,according to interim 12-week clinical data from a trial pilot conducted by the company.